Cargando…

Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis

BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Kun, Liu, Xianben, Xing, Wenqun, Sun, Haibo, Liu, Shilei, Li, Peng, Chen, Peinan, Zheng, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080310/
https://www.ncbi.nlm.nih.gov/pubmed/37033339
http://dx.doi.org/10.21037/tcr-22-2286
_version_ 1785020894253416448
author Gao, Kun
Liu, Xianben
Xing, Wenqun
Sun, Haibo
Liu, Shilei
Li, Peng
Chen, Peinan
Zheng, Yan
author_facet Gao, Kun
Liu, Xianben
Xing, Wenqun
Sun, Haibo
Liu, Shilei
Li, Peng
Chen, Peinan
Zheng, Yan
author_sort Gao, Kun
collection PubMed
description BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metastases compared with chemotherapy, and to analyze the factors that may affect the long-term survival of patients with pulmonary metastases. METHODS: We retrospectively analyzed the medical records of patients with pulmonary metastases from June 2012 to June 2019. Propensity score matching (PSM) was used to balance factors that might affect survival between the two groups. The data were analyzed by Kaplan-Meier survival analysis and Cox proportional hazards models to compare the survival of the surgery group and the chemotherapy group. RESULTS: A total of 202 patients with pulmonary metastases were enrolled in the study, with 43 patients in the surgery group and 43 in the chemotherapy group after screening and PSM. After PSM, patients in the surgery group had better survival than those in the chemotherapy group, with 5-year overall survival (OS) rates of 75.1% and 48.0%, respectively (P=0.017). Univariate analysis of the two groups of patients found that the treatment method, the number of metastases, and the total diameter of metastases were prognostic factors, but multivariate analysis did not find independent prognostic factors. In the surgical group, univariate analysis found that disease-free interval (DFI), the number of metastases, surgical methods, resection scope and surgical route were prognostic factors, and multivariate analysis showed that only DFI was an independent prognostic factor. In the chemotherapy group, DFI and the response of metastases to chemotherapy were found to be prognostic factors in univariate analysis, but no independent prognostic factors were found in multivariate analysis. CONCLUSIONS: Surgery does not provide a significant survival advantage. For patients undergoing surgery, longer DFI predicts better survival.
format Online
Article
Text
id pubmed-10080310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-100803102023-04-08 Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis Gao, Kun Liu, Xianben Xing, Wenqun Sun, Haibo Liu, Shilei Li, Peng Chen, Peinan Zheng, Yan Transl Cancer Res Original Article BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metastases compared with chemotherapy, and to analyze the factors that may affect the long-term survival of patients with pulmonary metastases. METHODS: We retrospectively analyzed the medical records of patients with pulmonary metastases from June 2012 to June 2019. Propensity score matching (PSM) was used to balance factors that might affect survival between the two groups. The data were analyzed by Kaplan-Meier survival analysis and Cox proportional hazards models to compare the survival of the surgery group and the chemotherapy group. RESULTS: A total of 202 patients with pulmonary metastases were enrolled in the study, with 43 patients in the surgery group and 43 in the chemotherapy group after screening and PSM. After PSM, patients in the surgery group had better survival than those in the chemotherapy group, with 5-year overall survival (OS) rates of 75.1% and 48.0%, respectively (P=0.017). Univariate analysis of the two groups of patients found that the treatment method, the number of metastases, and the total diameter of metastases were prognostic factors, but multivariate analysis did not find independent prognostic factors. In the surgical group, univariate analysis found that disease-free interval (DFI), the number of metastases, surgical methods, resection scope and surgical route were prognostic factors, and multivariate analysis showed that only DFI was an independent prognostic factor. In the chemotherapy group, DFI and the response of metastases to chemotherapy were found to be prognostic factors in univariate analysis, but no independent prognostic factors were found in multivariate analysis. CONCLUSIONS: Surgery does not provide a significant survival advantage. For patients undergoing surgery, longer DFI predicts better survival. AME Publishing Company 2023-02-13 2023-03-31 /pmc/articles/PMC10080310/ /pubmed/37033339 http://dx.doi.org/10.21037/tcr-22-2286 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Gao, Kun
Liu, Xianben
Xing, Wenqun
Sun, Haibo
Liu, Shilei
Li, Peng
Chen, Peinan
Zheng, Yan
Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title_full Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title_fullStr Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title_full_unstemmed Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title_short Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
title_sort treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080310/
https://www.ncbi.nlm.nih.gov/pubmed/37033339
http://dx.doi.org/10.21037/tcr-22-2286
work_keys_str_mv AT gaokun treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT liuxianben treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT xingwenqun treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT sunhaibo treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT liushilei treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT lipeng treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT chenpeinan treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis
AT zhengyan treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis